Furthering the potential for healthcare benefits from an expanding base of early-stage novel biomedical research at the University of Nottingham
Lead Research Organisation:
University of Nottingham
Department Name: UNLISTED
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Technical Summary
The Confidence in Concept scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach –– before seeking more substantive funding. It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.
Organisations
Publications
Burueva D
(2019)
In Situ Monitoring of Heterogeneous Catalytic Hydrogenation via 129 Xe NMR Spectroscopy and Proton MRI
in ACS Catalysis
Alyami A
(2021)
Quantitative Magnetic Resonance Imaging in Perianal Crohn's Disease at 1.5 and 3.0 T: A Feasibility Study.
in Diagnostics (Basel, Switzerland)
Description | Dr Serres, University of Nottingham RPA |
Amount | £10,000 (GBP) |
Organisation | University of Nottingham |
Sector | Academic/University |
Country | United Kingdom |
Start |
Description | IFP Studentship |
Amount | £51,000 (GBP) |
Organisation | IFP Energies Nouvelles |
Sector | Academic/University |
Country | France |
Start | 09/2021 |
End | 09/2024 |
Description | Innovate UK SMART Proof of Market award for Theagen: Transplantable Matrix for Ocular Surface Regeneration £25k (£41k, including matched funding from UoN). |
Amount | £25,000 (GBP) |
Funding ID | 700568 |
Organisation | Innovate UK |
Sector | Public |
Country | United Kingdom |
Start |
Description | MRC DPFS |
Amount | £2,085,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start |
Description | Production of a bivalent monoclonal antibody as a potent new immunotherapy for pancreatic cancer |
Amount | £100,757 (GBP) |
Funding ID | 200970/Z/16/Z |
Organisation | Wellcome Trust |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 07/2016 |
End | 01/2018 |
Description | Researcher Links: Workshop - Perspectives of Hyperpolarised MRI for Precision Medicine award to Pavlovskaya |
Amount | £48,344 (GBP) |
Funding ID | 2017-RLWK9-11351 |
Organisation | British Council |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 05/2018 |
End | 05/2019 |
Description | Scholarship for the National Biofilms Innovation Centre (NBIC) awarded to Miguel Camara |
Amount | £50,000 (GBP) |
Funding ID | VIA 062 |
Organisation | Cystic Fibrosis Trust |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 09/2019 |
End | 09/2023 |
Title | ANTI-TUMOUR IMMUNE RESPONSES TO MODIFIED SELF-EPITOPES |
Description | The present invention relates to modified citrullinated enolase peptides that can be used as targets for cancer immunotherapy. These peptides can be used as vaccines or as targets for monoclonal antibody (mAb) therapy. Such vaccines or mAbs may be used in the treatment of cancer. |
IP Reference | US2018207291 |
Protection | Patent application published |
Year Protection Granted | 2018 |
Licensed | Commercial In Confidence |
Impact | None |
Title | PRODUCTION OF HYPERPOLARIZED GAS |
Description | A method of removing buffer gas from a mixture comprising the buffer gas and hyperpolarized noble gas is described. The method includes reacting the buffer gas to produce a reaction product different to the buffer gas. The buffer gas may be reactively removed by one or more of oxidation, reduction, polymerization and binding reactions with solid surfaces. The buffer gas may be molecular hydrogen and/or molecular nitrogen. Apparatus for carrying out the method are also disclosed. |
IP Reference | WO2017042544 |
Protection | Patent application published |
Year Protection Granted | 2017 |
Licensed | No |
Impact | None to date |
Title | TRANSDUCTION |
Description | This invention relates to transduction of cargo molecules into living cells, such as protein transduction, in particular a delivery molecule for transduction of a cargo into a cell comprising: a cargo-binding molecule and/or a cargo; a glycosaminoglycan (GAG) binding element, which is capable of binding to GAG on the surface of the cell; and a protein transduction domain. Methods of transduction, methods of producing or modifying cargo for transduction, delivery molecules for transduction and methods of treatment using transduction, or using transduced cells are also provided. |
IP Reference | CA2971291 |
Protection | Patent application published |
Year Protection Granted | 2015 |
Licensed | Yes |
Impact | none |